Table 2.
The distribution of Gly482Ser genotypes in people with and without hypertension, and odds ratios and heterogeneity results for the hypertension analyses
| Cohort | Genotype Frequencies |
OR | 95% CI | P Value | ||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Without Hypertension |
With Hypertension | |||||||||
| Gly/Gly | Gly/Ser | Ser/Ser | Gly/Gly | Gly/Ser | Ser/Ser | Lower | Upper | |||
| Danish whites | ||||||||||
| Study 1 (Ref. 8)*† | 242 | 253 | 73 | 212 | 189 | 44 | 0.84 | 0.70 | 1.01 | 0.061 |
| Study 3 (Ref. 8)*† | 33 | 47 | 13 | 30 | 22 | 12 | 0.88 | 0.56 | 1.38 | 0.565 |
| Study 4 (Ref. 8)*† | 45 | 42 | 20 | 236 | 274 | 81 | 0.94 | 0.70 | 1.27 | 0.694 |
| Study 5 (Ref. 8)*† | 127 | 121 | 38 | 85 | 74 | 27 | 1.00 | 0.77 | 1.30 | 0.992 |
| Pima Indians† | 641 | 272 | 29 | 94 | 46 | 6 | 1.17 | 0.86 | 1.59 | 0.331 |
| UK whites | ||||||||||
| MRC Ely† | 184 | 251 | 68 | 85 | 90 | 16 | 0.66 | 0.47 | 0.92 | 0.013 |
| CCCS cases† | 66 | 79 | 21 | 164 | 147 | 37 | 0.81 | 0.62 | 1.07 | 0.138 |
| CCCS controls† | 102 | 104 | 31 | 109 | 111 | 50 | 1.17 | 0.92 | 1.50 | 0.203 |
| French Canadians (Ref. 2)† | 30 | 31 | 5 | 75 | 91 | 34 | 1.46 | 0.96 | 2.21 | 0.079 |
| EPIC | ||||||||||
| Obese† | 180 | 163 | 44 | 300 | 329 | 95 | 1.16 | 0.97 | 1.39 | 0.111 |
| Cohort† | 490 | 482 | 119 | 442 | 478 | 117 | 1.06 | 0.93 | 1.21 | 0.355 |
| Austrian whites (Ref. 7) | 286 | 315 | 103 | 231 | 231 | 47 | 0.80 | 0.67 | 0.95 | 0.010 |
| Overall | 0.97 | 0.87 | 1.08 | 0.585 | ||||||
n = 4,711 people with hypertension; n = 5,150 people without hypertension. OR, odds ratio; CI, confidence interval. P value for heterogeneity = 0.006.
*
Studies 1, 3, 4, and 5 correspond to the study numbers mentioned in the paper.
†
Studies with raw data.